Drugs / XTR003
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05136391 | Mar → Aug 2021 | coronary artery disorder | Sinotau Pharmaceutical Group | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07443696 | Dec 2025 → Aug 2026 overdue | cardiomyopathy, heart failure | Sinotau Pharmaceutical Group | Recruiting | No outcome recorded |
| Phase 2 | NCT05885854 | Dec 2021 → Mar 2023 | ischemic disease | Sinotau Pharmaceutical Group | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XTR003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05885854 ↗ |
| Modality | Diagnostic / imaging agent | “XTR003 is a PET imaging radiopharmaceutical agent” NCT05136391 ↗ |
| Route | Intravenous | “were intravenously injected with XTR003 (296-370 MBq)” PMID 39923833 ↗ Feb 2025 |